Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Collaboration    symbols : BLUE    save search

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease
Published: 2020-12-04 (Crawled : 16:00) - biospace.com/
BLUE | $0.9918 -3.71% -3.85% 5.8M twitter stocktwits trandingview |
Health Technology
| | O: -0.28% H: 2.43% C: 0.15%

collaboration disease stem cell trial phase 2
Gainers vs Losers
58% 42%

Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M twitter stocktwits trandingview |
Electronic Technology

VIAO | $0.265 -13.96% 35.85% 960K twitter stocktwits trandingview |
Electronic Technology

JAGX | $0.178 49.83% 33.26% 600M twitter stocktwits trandingview |
Health Technology

SXTC | $1.68 43.59% 30.36% 34M twitter stocktwits trandingview |
Health Technology

DYNT | $0.531 43.36% 30.24% 22M twitter stocktwits trandingview |
Health Technology

KA | $0.4796 41.06% 29.11% 5.3M twitter stocktwits trandingview |
Manufacturing

PALI | $5.86 40.87% 29.01% 29M twitter stocktwits trandingview |
Manufacturing

CLNN | $0.319 -3.74% 28.75% 6.3M twitter stocktwits trandingview |

BSGM | $1.52 38.18% 27.63% 3.3M twitter stocktwits trandingview |
Health Technology

MCBC | $13.67 37.66% 27.36% 2.2M twitter stocktwits trandingview |
Finance


Your saved searches
Save your searches and get alerts when important news are released.